Yufengchang Holdings Limited (HKG:8631)

Ligand Pharmaceuticals Revenue

In the fiscal year ending March 31, 2025, Yufengchang Holdings had annual revenue of 55.50M HKD, down -19.61%. Yufengchang Holdings had revenue of 23.01M in the quarter ending March 31, 2025, with 261.65% growth.

• Revenue: 55.50M
• Revenue Growth: -19.61%
• P/S Ratio: 0.32
• Revenue / Employee: 1.29M
• Employees: 43
• Market Cap: 17.60M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	55.50M	-13.53M	-19.61%
Mar 31, 2024	69.03M	1.31M	1.93%
Mar 31, 2023	67.72M	-163.19M	-70.67%
Mar 31, 2022	230.92M	-9.20M	-3.83%
Mar 31, 2021	240.11M	-111.00M	-31.61%